title: An animal model for open femur fracture and osteomyelitis--Part II: Immunomodulation with systemic IL-12.
abstract: Infection resulting from open fracture is a common problem in orthopedics. The purpose of this project was to study the effect of Interleukin-12 (IL-12) systemic therapy on a previously established open fracture model. One hundred seven male Sprague-Dawley rats were assigned to five groups: (1) normal (baseline), (2) control (controlled for anesthesia), (3) fracture, (4) staph, and (5) staph and IL-12 (SIL). Each group was divided into four time periods: 6, 10, 14, and 21 days after injury and fixation. The operative groups had a standardized femur fracture and fixation using a Kirschner wire as an intramedullary device. The two infection groups (staph and SIL) were inoculated with Staphylococcus aureus following fracture and fixed with an identical technique. The SIL group was treated with systemic IL-12 for a total of 10 doses over 10 days. Significantly decreased serum IL-12 levels were noted at day 10 in the operative groups compared to the normal and control groups. The SIL group showed significantly higher macrophage activation levels and total platelet counts at day 21 compared to all the other groups. The overall infection rate was not changed by IL-12 supplementation; however, bacterial qualitative growth scores were significantly lower in the SIL group at day 10, which corresponded to the lowest level of systemic IL-12 in the fracture group.
authors.affiliation: Department of Orthopaedics, West Virginia University, P.O. Box 9196 Health Sciences Center, Morgantown, West Virginia 26506-9196, USA. blindsey@hsc.wvu.edu
authors.forename: Brock A
authors.initials: BA
authors.lastname: Lindsey
authors.forename: Nina B
authors.initials: NB
authors.lastname: Clovis
authors.forename: E Suzanne
authors.initials: ES
authors.lastname: Smith
authors.forename: Sydha
authors.initials: S
authors.lastname: Salihu
authors.forename: David F
authors.initials: DF
authors.lastname: Hubbard
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000097:blood; D000818:Animals; D004195:Disease Models, Animal; D005264:Femoral Fractures / Q000097:blood / Q000382:microbiology* / Q000628:therapy; D005594:Fracture Fixation, Intramedullary / Q000009:adverse effects*; D017102:Fracture Healing / Q000187:drug effects; D005597:Fractures, Open / Q000097:blood / Q000382:microbiology* / Q000628:therapy; D056747:Immunomodulation / Q000187:drug effects; D018664:Interleukin-12 / Q000008:administration & dosage / Q000097:blood; D008297:Male; D010019:Osteomyelitis / Q000097:blood / Q000382:microbiology* / Q000517:prevention & control; D051381:Rats; D017207:Rats, Sprague-Dawley; D013203:Staphylococcal Infections / Q000097:blood / Q000382:microbiology / Q000517:prevention & control; D013211:Staphylococcus aureus / Q000187:drug effects; D013530:Surgical Wound Infection / Q000097:blood / Q000382:microbiology* / Q000517:prevention & control
chemical_list: D000276:Adjuvants, Immunologic; D018664:Interleukin-12